Alicia Dimitrijevic
Family · Clearwater, FLNPI 1386019685
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.3% of the total across 126 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 9.4% — the pattern of someone who eats at a lot of different presentations.
Across 126 payments — averaging $23.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$278
- Lundbeck LLC$254
- Genentech USA, Inc.$219
- Takeda Pharmaceuticals U.S.A., Inc.$198
- Lilly USA, LLC$180
- Sanofi$174
- plus $2K from 20 others
What the payments were for
- Food & beverage$2,90198%
- Education$512%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 14 | $278 |
| Lundbeck LLC | 9 | $254 |
| Genentech USA, Inc. | 9 | $219 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $198 |
| Lilly USA, LLC | 8 | $180 |
| Sanofi | 7 | $174 |
| AstraZeneca | 5 | $140 |
| Azurity Pharmaceuticals, Inc. | 6 | $138 |
| Biogen | 6 | $137 |
| Argenx US, Inc. | 6 | $135 |
| Otsuka America Pharmaceutical, Inc. | 6 | $129 |
| Eisai Inc. | 6 | $128 |
| TG Therapeutics, Inc. | 5 | $124 |
| AbbVie | 5 | $103 |
| UCB, Inc. | 4 | $99 |
| Novartis | 4 | $95 |
| EMD Serono, Inc. | 3 | $73 |
| CSL Behring | 3 | $64 |
| Neurocrine Biosciences, Inc. | 2 | $57 |
| Merz Pharmaceuticals, LLC | 2 | $50 |
| Teva Pharmaceuticals USA, Inc. | 3 | $47 |
| Cycle Pharmaceuticals Inc | 2 | $42 |
| Amgen | 1 | $27 |
| Sandoz | 1 | $23 |
| Idorsia Pharmaceuticals US Inc | 1 | $19 |
| Vanda Pharmaceuticals Inc. | 1 | $19 |
How this compares
$2,952 in reported general payments places this provider in the 85th percentile of 14,618 family providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dalfampridine ErDalfampridine | 17 | $3,004 |
| Gabapentin | 74 | $1,098 |
| Memantine Hcl | 33 | $1,007 |
| Duloxetine Hcl | 17 | $598 |
| Levetiracetam | 13 | $296 |
| Tizanidine Hcl | 16 | $236 |
| Baclofen | 14 | $188 |
| Ondansetron OdtOndansetron | 13 | $168 |
Paid to pharmacies, not to this prescriber.
Other family in Clearwater
- Marian FinehirshClearwater$31K
- Lewis HarringtonTampa$954K
- Danielle PharesFt Lauderdale$713K
- Donna OrtizOrlando$417K
- Patrick SzarazMiami$327K
- Deena RodneyMaitland$323K
- Yamila MelendezMiami$212K
- Holly BoydLand O Lakes$200K
- Rachael BuschLoxahatchee$189K
- Victor Tatis de la NuezMiramar$161K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.